Form 4: United Therapeutics CEO Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 24 and 25, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On June 24 and 25, 2024, Rothblatt exercised stock options and sold shares of United Therapeutics common stock.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both days, 3,600 stock options were exercised at a price of $129.49 per share.
- The sales on June 24 involved multiple transactions at weighted average prices ranging from $310.71 to $319.3333, with quantities ranging from 96 to 935 shares per transaction.
- The sales on June 25 involved multiple transactions at weighted average prices ranging from $318.4362 to $321.82, with quantities ranging from 164 to 1,853 shares per transaction.
- Following these transactions, Rothblatt directly owns 151,469 stock options and indirectly owns shares through various family trusts.
- The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive stock activity.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Industry Context
Executive stock sales are a common occurrence, and the use of a 10b5-1 plan indicates a pre-arranged strategy to avoid accusations of insider trading. The details of the plan are important for investors to understand the potential future impact on the stock.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The specifics of Rothblatt's 10b5-1 plan, such as the number of options and the duration, are typical for executives managing their equity holdings.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Expiration date of stock options |
| 2023-08-04 | Date of 10b5-1 trading plan establishment |
| 2024-06-24 | Date of first reported transaction (exercise and sale of stock options) |
| 2024-06-25 | Date of second reported transaction (exercise and sale of stock options) |
| 2024-06-26 | Date of Form 4 filing |
| 2024-08-31 | End date of 10b5-1 trading plan (alternative) |
| 2024-12-31 | Expiration date of tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.